Knockdown of NF-κB1 by shRNA Inhibits the Growth of Renal Cell Carcinoma In Vitro and In Vivo

Renal cell carcinoma (RCC) accounts for approximately 2%–3% of human malignancies and is the most aggressive among urologic tumors. Biological heterogeneity, drug resistance, and chemotherapy side effects are the biggest obstacles to the effective treatment of RCC. The NF-κB transcription factor is...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncol Res
Huvudupphovsmän: Ikegami, Amanda, Teixeira, Luiz Felipe S., Braga, Marina S., Dias, Matheus Henrique Dos S., Lopes, Eduardo C., Bellini, Maria Helena
Materialtyp: Artigo
Språk:Inglês
Publicerad: Cognizant Communication Corporation 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7844753/
https://ncbi.nlm.nih.gov/pubmed/29212573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504017X15120379906339
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk